Savara (SVRA) Current Assets (2010 - 2026)
Savara (SVRA) reported Current Assets of $209.3 million for Q1 2026, up 17.93% year-over-year from $177.4 million in Q1 2025, and down 13.39% on a QoQ basis from $241.6 million in Q4 2025.
Savara (SVRA) has 17 years of Current Assets data on file, last reported at $209.3 million in Q1 2026.
- Quarterly Current Assets rose 17.93% year-over-year to $209.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.3 million (up 17.93% YoY) and the FY2025 annual result came in at $241.6 million, up 19.53% from the prior year.
- Current Assets retreated to $209.3 million in Q1 2026 per SVRA's latest filing, from $241.6 million in the prior quarter.
- Across five years, Current Assets topped out at $241.6 million in Q4 2025 and bottomed at $107.9 million in Q2 2023.
- The 5-year median for Current Assets is $151.0 million (2025), against an average of $161.0 million.
- The widest annual swing landed in 2024, when Current Assets soared 33.1%; it then slumped 43.37% in 2025.
- Tracing SVRA's Current Assets over 5 years: stood at $129.0 million in 2022, then increased by 28.69% to $165.9 million in 2023, then climbed by 21.81% to $202.1 million in 2024, then gained by 19.53% to $241.6 million in 2025, then retreated by 13.39% to $209.3 million in 2026.
- Per Business Quant, the three latest SVRA Current Assets figures stand at $209.3 million (Q1 2026), $241.6 million (Q4 2025), and $128.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 209.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209.27 Mn |
| Dec 31, 2025 | 241.62 Mn |
| Sep 30, 2025 | 128.20 Mn |
| Jun 30, 2025 | 150.99 Mn |
| Mar 31, 2025 | 177.44 Mn |
| Dec 31, 2024 | 202.14 Mn |
| Sep 30, 2024 | 226.40 Mn |
| Jun 30, 2024 | 127.69 Mn |
| Mar 31, 2024 | 146.19 Mn |
| Dec 31, 2023 | 165.95 Mn |
| Sep 30, 2023 | 170.10 Mn |
| Jun 30, 2023 | 107.90 Mn |
| Mar 31, 2023 | 117.63 Mn |
| Dec 31, 2022 | 128.95 Mn |
| Sep 30, 2022 | 137.07 Mn |
| Jun 30, 2022 | 145.39 Mn |
| Mar 31, 2022 | 154.54 Mn |
| Dec 31, 2021 | 165.00 Mn |
| Sep 30, 2021 | 174.58 Mn |
| Jun 30, 2021 | 183.49 Mn |
| Mar 31, 2021 | 194.80 Mn |
| Dec 31, 2020 | 85.12 Mn |
| Sep 30, 2020 | 96.33 Mn |
| Jun 30, 2020 | 102.56 Mn |
| Mar 31, 2020 | 107.45 Mn |
| Dec 31, 2019 | 124.07 Mn |
| Sep 30, 2019 | 108.35 Mn |
| Jun 30, 2019 | 114.17 Mn |
| Mar 31, 2019 | 107.52 Mn |
| Dec 31, 2018 | 113.34 Mn |
| Sep 30, 2018 | 114.75 Mn |
| Jun 30, 2018 | 77.44 Mn |
| Mar 31, 2018 | 87.57 Mn |
| Dec 31, 2017 | 97.86 Mn |
| Sep 30, 2017 | 55.52 Mn |
| Jun 30, 2017 | 63.67 Mn |
| Mar 31, 2017 | 8.16 Mn |
| Dec 31, 2016 | 14.61 Mn |
| Sep 30, 2016 | 28.28 Mn |
| Jun 30, 2016 | 35.82 Mn |
| Mar 31, 2016 | 38.25 Mn |
| Dec 31, 2015 | 42.25 Mn |
| Sep 30, 2015 | 51.45 Mn |
| Jun 30, 2015 | 44.75 Mn |
| Mar 31, 2015 | 50.56 Mn |
| Dec 31, 2014 | 58.40 Mn |
| Sep 30, 2014 | 44.06 Mn |
| Jun 30, 2014 | 47.56 Mn |
| Mar 31, 2014 | 50.61 Mn |
| Dec 31, 2013 | 45.53 Mn |
| Sep 30, 2013 | 49.93 Mn |
| Jun 30, 2013 | 54.12 Mn |
| Mar 31, 2013 | 32.53 Mn |
| Dec 31, 2012 | 37.17 Mn |
| Sep 30, 2012 | 41.64 Mn |
| Jun 30, 2012 | 44.29 Mn |
| Mar 31, 2012 | 47.31 Mn |
| Dec 31, 2011 | 51.79 Mn |
| Sep 30, 2011 | 39.04 Mn |
| Jun 30, 2011 | 42.73 Mn |
| Dec 31, 2010 | 28.41 Mn |